UnitedHealth Group (NYSE:UNH) had its price target boosted by analysts at Oppenheimer from $260.00 to $240.00 in a report released on Wednesday. The firm currently has an “outperform” rating on the healthcare conglomerate’s stock. Oppenheimer’s target price suggests a potential upside of 3.05% from the company’s previous close. Oppenheimer also issued estimates for UnitedHealth Group’s Q1 2019 earnings at $2.88 EPS, Q2 2019 earnings at $3.05 EPS, Q3 2019 earnings at $3.26 EPS, Q4 2019 earnings at $3.15 EPS and FY2019 earnings at $12.33 EPS.
UNH has been the subject of several other research reports. Leerink Swann reissued a “buy” rating and issued a $240.00 price objective (up previously from $225.00) on shares of UnitedHealth Group in a research note on Wednesday, October 18th. Zacks Investment Research raised shares of UnitedHealth Group from a “hold” rating to a “buy” rating and set a $219.00 price objective for the company in a research note on Thursday, September 21st. Cantor Fitzgerald raised their price objective on shares of UnitedHealth Group to $225.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 18th. Wells Fargo & Co reissued an “outperform” rating and issued a $245.00 price objective (up previously from $230.00) on shares of UnitedHealth Group in a research note on Wednesday, November 29th. Finally, Citigroup raised their price objective on shares of UnitedHealth Group from $235.00 to $268.00 and gave the stock a “buy” rating in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and twenty-five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $239.70.
Shares of UnitedHealth Group (NYSE UNH) traded up $4.26 during midday trading on Wednesday, reaching $232.90. 6,852,400 shares of the company’s stock traded hands, compared to its average volume of 3,225,820. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $230,080.00, a P/E ratio of 21.75, a P/E/G ratio of 1.53 and a beta of 0.66. UnitedHealth Group has a twelve month low of $156.09 and a twelve month high of $235.00.
UnitedHealth Group (NYSE:UNH) last announced its quarterly earnings data on Tuesday, January 16th. The healthcare conglomerate reported $2.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.50 by $0.09. The business had revenue of $52.06 billion during the quarter, compared to the consensus estimate of $51.57 billion. UnitedHealth Group had a net margin of 4.50% and a return on equity of 21.52%. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the firm earned $2.11 earnings per share. research analysts predict that UnitedHealth Group will post 9.99 earnings per share for the current fiscal year.
In related news, insider Thomas E. Roos sold 975 shares of UnitedHealth Group stock in a transaction that occurred on Thursday, October 19th. The shares were sold at an average price of $205.47, for a total transaction of $200,333.25. Following the transaction, the insider now directly owns 24,630 shares of the company’s stock, valued at $5,060,726.10. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Larry C. Renfro sold 22,598 shares of UnitedHealth Group stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $221.75, for a total transaction of $5,011,106.50. Following the transaction, the chief executive officer now directly owns 195,314 shares in the company, valued at $43,310,879.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,630 shares of company stock worth $7,669,416. 0.89% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently modified their holdings of UNH. Iberiabank Corp increased its holdings in UnitedHealth Group by 3.0% during the second quarter. Iberiabank Corp now owns 4,311 shares of the healthcare conglomerate’s stock valued at $799,000 after buying an additional 127 shares during the period. Private Trust Co. NA increased its holdings in UnitedHealth Group by 10.1% during the second quarter. Private Trust Co. NA now owns 8,150 shares of the healthcare conglomerate’s stock valued at $1,511,000 after buying an additional 748 shares during the period. Covenant Asset Management LLC increased its holdings in UnitedHealth Group by 2.7% during the second quarter. Covenant Asset Management LLC now owns 7,185 shares of the healthcare conglomerate’s stock valued at $1,332,000 after buying an additional 190 shares during the period. ETF Portfolio Partners Inc. purchased a new position in UnitedHealth Group during the second quarter valued at approximately $206,000. Finally, Central Bank & Trust Co. increased its holdings in UnitedHealth Group by 0.8% during the second quarter. Central Bank & Trust Co. now owns 17,992 shares of the healthcare conglomerate’s stock valued at $3,336,000 after buying an additional 134 shares during the period. 86.09% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “UnitedHealth Group (UNH) Given New $240.00 Price Target at Oppenheimer” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/17/unitedhealth-group-unh-given-new-240-00-price-target-at-oppenheimer.html.
About UnitedHealth Group
UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.